John McConnell, MD
Pulmonary Disease · Louisville, KYNPI 1902831761
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $595,531 of the $864,445 with a category attached, or 68.9%. Actelion Pharmaceuticals US, Inc. accounts for 66.5% of it on its own, with 26 other manufacturers making up the rest. Among pulmonary disease clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 922 payments — averaging $937.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$575K
- Bayer$158K
- Merck$90K
- Pfizer$15K
- Johnson & Johnson$9K
- United Therapeutics Corporation$9K
- plus $9K from 21 others
Across 233 payments — averaging $11,473 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.5M
- Janssen Research & Development, LLC$314K
- Actelion Pharmaceuticals, Ltd$234K
- United Therapeutics Corporation$193K
- Sumitomo Pharma America, Inc.$150K
- Bayer$105K
- plus $176K from 6 others
What the payments were for
- Consulting fees$125,25514%
- Speaking & faculty fees$595,53169%
- Travel & lodging$116,35013%
- Food & beverage$27,1103%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 522 | $575,067 |
| Bayer | 148 | $157,937 |
| Merck | 122 | $90,483 |
| Pfizer | 6 | $14,594 |
| Johnson & Johnson | 10 | $9,274 |
| United Therapeutics Corporation | 33 | $8,504 |
| Astellas Pharma US Inc | 3 | $2,457 |
| Actelion Pharmaceuticals, Ltd | 16 | $2,080 |
| Mylan Specialty L.p. | 2 | $816 |
| Sandoz | 6 | $427 |
| Insmed, Inc. | 17 | $386 |
| Boehringer Ingelheim | 5 | $377 |
| AstraZeneca | 4 | $350 |
| GSK | 6 | $272 |
| Inari Medical, Inc. | 1 | $231 |
| Vero Biotech Inc. | 2 | $219 |
| La Jolla Pharmaceutical Company | 2 | $177 |
| Abbott | 1 | $139 |
| Genentech USA, Inc. | 7 | $124 |
| Chiesi USA, Inc. | 1 | $110 |
| Edwards Lifesciences | 1 | $108 |
| Janssen Research & Development, LLC | 2 | $104 |
| Liquidia Technologies, Inc. | 1 | $81 |
| Philips North America LLC | 1 | $73 |
| Novartis | 1 | $23 |
| AbbVie | 1 | $18 |
| Grifols USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$466,914
- OPSUMIT$397,550
- Adempas$150,626
- WINREVAIR$62,852
- REMODULIN$6,935
- VELETRI$4,725
- CRESEMBA$2,449
- BOSENTAN$1,465
- Yupelri$800
- TREPROSTINIL$276
- FLOWTRIEVER CATHETER, S$231
- CT THROMBECTOMY SYSTEM KIT$231
- TYVASO$213
- Genosyl$204
- CARDIOMEMS$139
- Arikayce$137
- FASENRA$123
- OFEV$122
- AREXVY$113
- All-In-One$112
How this compares
$864,445 in reported general payments places this provider in the 95th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 946 | $11,971,909 |
| UptraviSelexipag | 476 | $10,681,793 |
| AdempasRiociguat | 610 | $8,612,895 |
| WinrevairSotatercept-Csrk | 238 | $3,930,503 |
| OfevNintedanib Esylate | 55 | $717,806 |
| OpsynviMacitentan/Tadalafil | 41 | $525,341 |
| Tyvaso DpiTreprostinil | 18 | $435,554 |
| Ambrisentan | 114 | $288,070 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 23 | $202,547 |
| LetairisAmbrisentan | 17 | $200,898 |
| AdcircaTadalafil | 38 | $153,785 |
| Orenitram ErTreprostinil Diolamine | 20 | $152,758 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 164 | $144,926 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $73,306 |
| RevatioSildenafil Citrate | 12 | $62,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi | $575,067 | $23,179,0441,463 claims |
| BayerAdempas | $157,937 | $8,612,895610 claims |
| MerckWinrevair | $90,483 | $3,930,503238 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $377 | $777,865141 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $272 | $203,208290 claims |
| Grifols USA, LLCProlastin C | $14 | $202,54723 claims |
| United Therapeutics CorporationAdcirca | $8,504 | $153,78538 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $350 | $84,392144 claims |
| Johnson & JohnsonVeletri | $9,274 | $36,71512 claims |
| PfizerEliquis | $14,594 | $36,32751 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Louisville
- Harold HallerLouisville$340K
- Samantha BaahLouisville$226K
- Karim El-KershLouisville$180K
- Josephine MeiLouisville$101K
- Maroun GhosseinLouisville$34K
- Moutaz Al NabhanLouisville$24K
- Sally SulimanLouisville$21K
- Mark EsterleLouisville$19K
- Kenneth AndersonLouisville$16K
- Mohamed SaadLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.